Shopping Cart
Remove All
Your shopping cart is currently empty
Glembatumumab
Catalog No. T77439 Copy Product Info
🥰Excellent
Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. It is a naked antibody to Glembatumumab vedotin and can be used to study antibody-activated molecule couplings (Glembatumumab vedotin).
Glembatumumab
Copy Product Info🥰Excellent
Catalog No. T77439
Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. It is a naked antibody to Glembatumumab vedotin and can be used to study antibody-activated molecule couplings (Glembatumumab vedotin).
Glembatumumab
Cas No. 1020264-78-1
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $263 | In Stock | In Stock | |
| 5 mg | $588 | In Stock | In Stock | |
| 10 mg | $947 | - | In Stock | |
| 25 mg | $1,380 | - | In Stock | |
| 50 mg | $1,890 | - | In Stock | |
| 100 mg | $2,550 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.31% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. It is a naked antibody to Glembatumumab vedotin and can be used to study antibody-activated molecule couplings (Glembatumumab vedotin). |
| In vitro | Glembatumumab vedotin (CR011-vcMMAE) exhibits minimal growth inhibition at a concentration of 0.16 μg/mL in UACC62 melanoma cells without prior MEK inhibitor pretreatment for 72 hours. In contrast, the same dose of CR011-vcMMAE shows stronger growth inhibition in UACC62 cells pre-treated with a MEK inhibitor[1]. |
| In vivo | Glembatumumab vedotin, administered via intravenous injection at a dose of 2.5 mg/kg three times within 7 days, inhibits tumor growth and demonstrates good tolerance in CB17SC scid?/? female xenograft mice[2]. |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | GPNMB |
| Molecular Weight | 145.56 kDa |
| Cas No. | 1020264-78-1 |
| Isotype | Human IgG2 kappa |
| Recommended Isotype Control |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Glembatumumab | purchase Glembatumumab | Glembatumumab cost | order Glembatumumab | Glembatumumab in vivo | Glembatumumab in vitro | Glembatumumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.